A new medicine for anthrax, developed by Kirov scientists as assigned by the Foundation for Advanced Research (FAR), causes no severe allergic reactions.

"The novelty of the approach is that in order to reduce fatal outcomes in terminal states, the tobramycin antibiotic is used, which has germicidal effect on the causative agent of anthrax. It is followed with intravenous administration of human antianthrax immunoglobulin, which has the ability to bind the resulting toxins and increase the humoral immunity level"- the report reads.

The new medication has been developed by specialists of the Vostok company, the Kirov Hematology and Blood Transfusion Scientific Research Institute of the Federal Medical Biological Agency and the 48th Central Research Institute of the RF Ministry of Defense.

The drug is intended for emergency prevention and treatment of anthrax in humans.

As the Foundation for Advanced Research explains, the major problem in anthrax treatment is the low efficiency of antibiotic therapy for pulmonary, intestinal and toxic forms of the disease, the cases that are most common with inhalation infection. With these clinical forms of anthrax, human anti-anthrax immunoglobulin is required to be used along with antibiotic therapy. At the same time, horse immunoglobulin is presently used, which causes severe allergic reactions in children and with repeated use.

The new drug efficacy has been experimentally confirmed in laboratories.